Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea

References

• LemboAJLacyBEZuckermanMJEluxadoline for irritable bowel syndrome with diarrheaN Engl J Med2016374324225326789872
   PubMed Web of Science ®Google Scholar
• LongstrethGFThompsonWGCheyWDHoughtonLAMearinFSpillerRCFunctional bowel disordersGastroenterology200613051480149116678561
   PubMed Web of Science ®Google Scholar
• MearinFLacyBEChangLBowel disordersGastroenterology201615013931407
   Web of Science ®Google Scholar
• LovellRMFordACGlobal prevalence of and risk factors for irritable bowel syndrome: a meta-analysisClin Gastroenterol Hepatol2012107712721.e422426087
   PubMed Web of Science ®Google Scholar
• CanavanCWestJCardTThe epidemiology of irritable bowel syndromeClin Epidemiol20146718024523597
   PubMed Web of Science ®Google Scholar
• DrossmanDAPatrickDLWhiteheadWEFurther validation of the IBS-QOL: a disease-specific quality-of-life questionnaireAm J Gastroenterol2000954999100710763950
   PubMed Web of Science ®Google Scholar
• PatrickDLDrossmanDAFrederickIODiCesareJPuderKLQuality of life in persons with irritable bowel syndrome: development and validation of a new measureDig Dis Sci19984324004119512138
   PubMed Web of Science ®Google Scholar
• EndoYShojiTFukudoSEpidemiology of irritable bowel syndromeAnn Gastroenterol20152815815925830818
   PubMed Web of Science ®Google Scholar
• LiuJHouXA review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in ChinaJ Gastroenterol Hepatol201126suppl 3889321443718
   PubMed Web of Science ®Google Scholar
• CamilleriMPeripheral mechanisms in irritable bowel syndromeN Engl J Med20123671626163523094724
   PubMed Web of Science ®Google Scholar
• SahaLIrritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicineWorld J Gastroenterol2014206759677324944467
   PubMed Web of Science ®Google Scholar
• KellowJEPathophysiology and management of irritable bowel syndromeKorean J Intern Med20011613714611769571
   PubMedGoogle Scholar
• DrossmanDAFunctional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IVGastroenterology201615012621279
   Web of Science ®Google Scholar
• Van OudenhoveLCrowellMDDrossmanDABiopsychosocial aspects of functional gastrointestinal disordersGastroenterology201615013551367
   Web of Science ®Google Scholar
• FrancisCYMorrisJWhorwellPJThe irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progressAliment Pharmacol Ther19971123954029146781
   PubMed Web of Science ®Google Scholar
• FukudoSKanekoHAkihoHEvidence-based clinical practice guidelines for irritable bowel syndromeJ Gastroenterol2015501113025500976
   PubMed Web of Science ®Google Scholar
• CamilleriMKatzkaDAIrritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndromeAm J Physiol Gastrointest Liver Physiol201230210G1075G108422403795
   PubMed Web of Science ®Google Scholar
• CamilleriMSellinJHBarrettKEPathophysiology, evaluation, and management of chronic watery diarrheaGastroenterology2017152515532.e227773805
   PubMed Web of Science ®Google Scholar
• ScarpelliniELaterzaLIaniroGTackJAbenavoliLGasbarriniAEluxadoline for the treatment of diarrhoea-predominant irritable bowel syndromeExpert Opin Pharmacother201617101395140227267380
   PubMed Web of Science ®Google Scholar
• Garnock-JonesKPEluxadoline: first global approvalDrugs201575111305131026149369
   PubMed Web of Science ®Google Scholar
• NICE [webpage on the Internet]Irritable Bowel Syndrome (Diarrhoea) – Eluxadoline [ID870] [Internet]2017 Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10031Accessed May 20, 2017
   Google Scholar
• SobczakMSalagaMStorrMAFichnaJPhysiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectivesJ Gastroenterol2014491244523397116
   PubMed Web of Science ®Google Scholar
• MosinskaPZielinskaMFichnaJExpression and physiology of opioid receptors in the gastrointestinal tractCurr Opin Endocrinol Diabetes Obes201623131026702845
   PubMedGoogle Scholar
• CorsettiMWhorwellPNovel pharmacological therapies for irritable bowel syndromeExpert Rev Gastroenterol Hepatol201710807815
   Web of Science ®Google Scholar
• CorsettiMWhorwellPNew therapeutic options for IBS: the role of the first in class mixed micro-opioid receptor agonist and delta-opioid receptor antagonist (mudelta) eluxadolineExpert Rev Gastroenterol Hepatol20171128529228276811
   PubMed Web of Science ®Google Scholar
• KurzASesslerDIOpioid-induced bowel dysfunction: pathophysiology and potential new therapiesDrugs200363764967112656645
   PubMed Web of Science ®Google Scholar
• WadePRPalmerJMMcKenneySModulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist/micro opioid receptor antagonistBr J Pharmacol20121671111112522671931
   PubMed Web of Science ®Google Scholar
• KeatingGMEluxadoline: a review in diarrhoea-predominant irritable bowel syndromeDrugs20177791009101628493170
   PubMed Web of Science ®Google Scholar
• CashBDLacyBERaoTEarnestDLRifaximin and eluxadoline – newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?Expert Opin Pharmacother201617331132226559529
   PubMed Web of Science ®Google Scholar
• LacyBEEmerging treatments in neurogastroenterology: eluxadoline – a new therapeutic option for diarrhea-predominant IBSNeurogastroenterol Motil2016281263526690872
   PubMed Web of Science ®Google Scholar
• Sobolewska-WlodarczykAWlodarczykMStorrMFichnaJClinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndromeTher Clin Risk Manag20161277177527257381
   PubMed Web of Science ®Google Scholar
• DavenportJMCovingtonPBonifacioLMcIntyreGVenitzJEffect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadolineJ Clin Pharmacol201555553454225491493
   PubMed Web of Science ®Google Scholar
• FujitaWGomesIDoveLSProhaskaDMcIntyreGDeviLAMolecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromersBiochem Pharmacol201492344845625261794
   PubMed Web of Science ®Google Scholar
• Levy-CoopermanNMcIntyreGBonifacioLAbuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed mu- and kappa-opioid receptor agonist and delta-opioid receptor antagonistJ Pharmacol Exp Ther201635947148127647873
   PubMed Web of Science ®Google Scholar
• RivkinARybalovSUpdate on the management of diarrhea-predominant irritable bowel syndrome: focus on rifaximin and eluxadolinePharmacotherapy201636330031626971716
   PubMed Web of Science ®Google Scholar
• Eluxadoline (Viberzi) for irritable bowel syndrome with diarrheaMed Lett Drugs Ther2016584526714241
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGGroup PPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementJ Clin Epidemiol2009621006101219631508
   PubMed Web of Science ®Google Scholar
• DoveLSLemboARandallCWEluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 studyGastroenterology20131452329338.e123583433
   PubMed Web of Science ®Google Scholar
• CashBDLacyBESchoenfeldPSDoveLSCovingtonPSSafety of eluxadoline in patients with irritable bowel syndrome with diarrheaAm J Gastroenterol2017112236537427922029
   PubMed Web of Science ®Google Scholar
• CheyWDDoveLSAndraeDACovingtonPSEarly response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studiesAliment Pharmacol Ther201745101319132828326568
   PubMed Web of Science ®Google Scholar
• LacyBECheyWDCashBDLemboAJDoveLSCovingtonPSEluxadoline efficacy in IBS-D patients who report prior loperamide useAm J Gastroenterol2017112692493228417992
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGotzschePCThe Cochrane collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• FragkosKCZarate-LopezNFrangosCCWhat about clonidine for diarrhoea? A systematic review and meta-analysis of its effect in humansTherap Adv Gastroenterol201693282301
   Web of Science ®Google Scholar
• FragkosKCTsagrisMFrangosCCExploring the distribution for the estimator of Rosenthal’s “fail-safe’ number of unpublished studies in meta-analysisCommun Stat Theory Methods20174656725684
   Web of Science ®Google Scholar
• DrossmanDAThe functional gastrointestinal disorders and the Rome III processGastroenterology20061301377139016678553
   PubMed Web of Science ®Google Scholar
• BarbaraGRevival of 5-HT3 antagonism as treatment of IBS-D?Gut2014631530153224465028
   PubMed Web of Science ®Google Scholar
• LemboAPimentelMRaoSSRepeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndromeGastroenterology201615161113112127528177
   PubMed Web of Science ®Google Scholar
• RahimiRNikfarSRezaieAAbdollahiMEfficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysisWorld J Gastroenterol200915131548155319340896
   PubMed Web of Science ®Google Scholar
• Foxx-OrensteinAENew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsTherap Adv Gastroenterol201693354375
   PubMed Web of Science ®Google Scholar
• FordACMoayyediPLacyBEAmerican College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipationAm J Gastroenterol2014109suppl 1S2S26 quiz S725091148
   PubMed Web of Science ®Google Scholar
• PimentelMLemboACheyWDTARGET Study GroupRifaximin therapy for patients with irritable bowel syndrome without constipationN Engl J Med20113641223221208106
   PubMed Web of Science ®Google Scholar
• WoodRFraserLABrewsterDHGardenOJEpidemiology of gallbladder cancer and trends in cholecystectomy rates in Scotland, 1968–1998Eur J Cancer200339142080208612957463
   PubMed Web of Science ®Google Scholar
• KennedyTMJonesRHEpidemiology of cholecystectomy and irritable bowel syndrome in a UK populationBr J Surg200087121658166311122180
   PubMed Web of Science ®Google Scholar
• JaffeJHKanzlerMGreenJAbuse potential of loperamideClin Pharmacol Ther1980288128197438696
   PubMed Web of Science ®Google Scholar
• FantRVHenningfieldJECashBDDoveLSCovingtonPSEluxadoline demonstrates a lack of abuse potential in phase 2 and 3 studies of patients with irritable bowel syndrome with diarrheaClin Gastroenterol Hepatol201715710211029.e628167156
   PubMed Web of Science ®Google Scholar
• ChenLIlhamSJFengBPharmacological approach for managing pain in irritable bowel syndrome: a review articleAnesth Pain Med201772e4274728824858
   PubMedGoogle Scholar